RAPT THERAPEUTICS, INC. (RAPT): Price and Financial Metrics


RAPT THERAPEUTICS, INC. (RAPT): $32.90

0.60 (+1.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RAPT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 504

in industry

RAPT POWR Grades


  • Sentiment is the dimension where RAPT ranks best; there it ranks ahead of 61.27% of US stocks.
  • RAPT's strongest trending metric is Momentum; it's been moving down over the last 51 weeks.
  • RAPT ranks lowest in Momentum; there it ranks in the 4th percentile.

RAPT Stock Summary

  • RAPT Therapeutics Inc's stock had its IPO on November 1, 2019, making it an older stock than only 3.33% of US equities in our set.
  • For RAPT, its debt to operating expenses ratio is greater than that reported by only 0.45% of US equities we're observing.
  • With a price/sales ratio of 193.55, RAPT Therapeutics Inc has a higher such ratio than 97.82% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to RAPT Therapeutics Inc are ATRA, MORF, DRNA, RNA, and NKTR.
  • Visit RAPT's SEC page to see the company's official filings. To visit the company's web site, go to www.rapt.com.

RAPT Valuation Summary

  • RAPT's price/sales ratio is 196; this is 5057.89% higher than that of the median Healthcare stock.
  • Over the past 22 months, RAPT's EV/EBIT ratio has gone down 9.1.
  • RAPT's price/sales ratio has moved NA NA over the prior 22 months.

Below are key valuation metrics over time for RAPT.

Stock Date P/S P/B P/E EV/EBIT
RAPT 2021-08-31 196.0 4.4 -16.1 -14.8
RAPT 2021-08-30 192.3 4.3 -15.8 -14.5
RAPT 2021-08-27 191.7 4.3 -15.7 -14.4
RAPT 2021-08-26 192.8 4.4 -15.8 -14.5
RAPT 2021-08-25 193.1 4.4 -15.8 -14.5
RAPT 2021-08-24 191.3 4.3 -15.7 -14.4

RAPT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RAPT has a Quality Grade of D, ranking ahead of 16.79% of graded US stocks.
  • RAPT's asset turnover comes in at 0.034 -- ranking 347th of 680 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows RAPT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.034 1 -0.626
2021-03-31 0.043 1 -0.647
2020-12-31 0.037 1 -0.651
2020-09-30 0.030 1 -0.885
2020-06-30 0.020 1 -1.302
2019-12-31 0.000 NA 97.551

RAPT Price Target

For more insight on analysts targets of RAPT, see our RAPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $62.14 Average Broker Recommendation 1.43 (Moderate Buy)

RAPT Stock Price Chart Interactive Chart >

Price chart for RAPT

RAPT Price/Volume Stats

Current price $32.90 52-week high $43.26
Prev. close $32.30 52-week low $14.63
Day low $31.50 Volume 165,100
Day high $33.22 Avg. volume 441,978
50-day MA $33.21 Dividend yield N/A
200-day MA $26.03 Market Cap 970.16M

RAPT THERAPEUTICS, INC. (RAPT) Company Bio


Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.


RAPT Latest News Stream


Event/Time News Detail
Loading, please wait...

RAPT Latest Social Stream


Loading social stream, please wait...

View Full RAPT Social Stream

Latest RAPT News From Around the Web

Below are the latest news stories about RAPT Therapeutics Inc that investors may wish to consider to help them evaluate RAPT as an investment opportunity.

RAPT Therapeutics Announces Late-Breaking Oral Presentation of Positive Results from Phase 1b Trial of RPT193 at the 30th European Academy of Dermatology and Venereology Congress

Benefit demonstrated in all key exploratory efficacy endpoints - EASI, EASI-50, EASI-75, EASI-90, vIGA, BSA and pruritus NRS-3 and 4 - with once-daily, oral treatment with RPT193Continued improvement observed 2 weeks after end of treatment on multiple endpoints SOUTH SAN FRANCISCO, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecul

Yahoo | September 30, 2021

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | September 23, 2021

RAPT Therapeutics to Present at the 2021 Cantor Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and CEO, will present at the 2021 Cantor Virtual Healthcare Conference on Monday, September 27, 2021 at 2:00 p.m. EST.

Intrado Digital Media | September 20, 2021

RAPT Therapeutics to Present RPT193 Phase 1b Data at 30th European Academy of Dermatology and Venereology Congress

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that it will present clinical safety and efficacy data from the RPT193 Phase 1b monotherapy trial in patients with moderate-to-severe atopic dermatitis at the virtual 30 th European Academy of Dermatology and Venereology Congress (EADV) held September 29, 2021 October 2, 2021.

Intrado Digital Media | September 20, 2021

Chief Medical Officer Of Rapt Therapeutics Makes $108.12 Thousand Sale

William Ho, Chief Medical Officer at Rapt Therapeutics (NASDAQ:RAPT), made a large insider sell on September 8, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Ho sold 3,000 shares of Rapt Therapeutics at a price of $36.04 per share. The total transaction amounted to $108,120. Ho still owns a total of 65,106 of Rapt Therapeutics worth, $2,254,627. Rapt Therapeutics shares are trading down 4.02% at $34.63 at t

Yahoo | September 10, 2021

Read More 'RAPT' Stories Here

RAPT Price Returns

1-mo -16.65%
3-mo -0.21%
6-mo 59.40%
1-year -19.50%
3-year N/A
5-year N/A
YTD 66.58%
2020 -28.47%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7932 seconds.